Endometriosis: A Disease More Terrifying Than Cancer?

2025-06-14
Endometriosis: A Disease More Terrifying Than Cancer?

Endometriosis is a mysterious disease whose cause remains unknown, bearing a striking resemblance to cancer yet lacking effective treatments. This article explores the disease's origins, its connection to cancer, and the limitations of current treatments. It also highlights the severely underestimated prevalence and the critical lack of research funding, calling for more attention and investment in research on this disease.

Read more

Molecular Dynamics: A Deep Dive from Theory to Practice

2025-06-10
Molecular Dynamics: A Deep Dive from Theory to Practice

This article provides a comprehensive overview of molecular dynamics (MD) simulations, explaining the underlying principles and practical applications. Using protein folding as a central example, it details the steps involved: force fields, energy minimization, equilibration, and production simulations. Advanced topics such as quantum effects, enhanced sampling, and free energy calculations are also explored. Two case studies demonstrate the use of MD in drug discovery and influenza adaptation research. The article concludes by highlighting the limitations and future directions of MD simulations.

Read more

Immunotherapy Timing: A Game Changer?

2025-06-08
Immunotherapy Timing: A Game Changer?

A study suggests that administering immunotherapy infusions before 3 PM significantly improves cancer patient outcomes compared to later infusions. Patients receiving treatment earlier experienced longer disease control (11.3 months vs. 5.7 months) and median survival (at least 23.2 months vs. 16.4 months). This seemingly risk-free and cost-free improvement has sparked debate. While some skepticism remains, multiple retrospective studies and a randomized clinical trial support the finding, suggesting optimal immunotherapy timing may be earlier in the day, potentially linked to the body's circadian rhythm. Further research is needed to understand the mechanism, but this could lead to updated immunotherapy guidelines.

Read more

AI-Designed Antivenom: A Solution to the Antivenom Shortage?

2025-05-08
AI-Designed Antivenom: A Solution to the Antivenom Shortage?

Scientists have successfully used AI to design proteins that bind to neurotoxic proteins in snake venom, showing efficacy in mice. However, this raises the question: why design new binders when antivenoms already exist? The article delves into the challenges of antivenom production: high costs, shortages, and the extreme heterogeneity of snake venoms. While AI-designed antivenoms offer potential solutions, their success hinges on scalable, low-cost production and overcoming market-based challenges. The article also explores a recent study creating a 'universal' antivenom from a man repeatedly bitten by snakes, highlighting both the promise and the persistent economic hurdles.

Read more
Tech Medicine

Recursion Pharmaceuticals Ditches Cell Painting for Brightfield Imaging

2024-12-15
Recursion Pharmaceuticals Ditches Cell Painting for Brightfield Imaging

Recursion Pharmaceuticals, a biotech leveraging machine learning for drug discovery, recently announced a surprising shift: abandoning its signature cell painting technique in favor of traditional brightfield imaging. This article delves into the reasons behind this change. Advances in deep learning allow models to effectively process raw images, diminishing the value of cell painting's fluorescent dyes for contrast enhancement. Brightfield imaging offers advantages in cost, ease of implementation, and compatibility with live-cell time-lapse microscopy, opening up possibilities for studying cellular dynamics. Despite the seemingly risky move, internal testing at Recursion shows brightfield imaging yielding comparable or even superior results in predicting drug perturbations.

Read more